Focal treatment is not a shortcut around staging. It depends on accurate localisation of tumour, understanding of risk outside the visible lesion, and honest discussion of what is proven versus still evolving in the literature.
mpMRI is a key tool in modern prostate cancer pathways. It can help with diagnosis, targeted biopsy, local staging, surveillance on active surveillance, and planning where focal therapy might be discussed.1 More accurate sampling and localisation supports the idea of treating a dominant area while leaving more of the gland intact, when the clinical picture fits.2
MRI is also used in other organs when ablation or focal strategies are planned, but the exact sequences and reporting standards differ by site and speciality.
For the prostate, combining MRI with ultrasound to fuse images allows targeted cores from suspicious areas, often alongside systematic sampling according to unit protocol. The aim is to reduce under-diagnosis of higher-grade disease outside the index lesion.
Many centres discuss complex localised cancer in a multidisciplinary meeting (radiology, pathology, urology, radiation oncology). Recommendations are not binding on you, but they help ensure options are considered consistently.
You can ask for a second opinion on imaging, diagnosis and treatment options before you decide.
